Table 1.
Company | # of SAR point | Date | Reference |
---|---|---|---|
AstraZeneca | 150 million single-shot SAR points, 14 milliona CR SAR points | Up to 2008 | (Proffitt, 2008; Muresan et al., 2011) |
Boehringer Ingelheim | 260 million single-shot SAR points, 7 million CR SAR points | Up to 2011 | (Beck, 2012) |
Pfizer | 0.6 million CR SAR points | Up to 2005 | (Paolini et al., 2006) |
Johnson & Johnson | 30 million SAR points | Up to 2006 | (Agrafiotis et al., 2007) |
a) This number includes external sources, up to 2012.